stockrowHaleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Free cash flow
Haleon PLC Sponsored ADR's free cash flow for fiscal 2025 was $2.9B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.6B. Over the past ten years it has ranged from $1.0B (fiscal 2019) to $2.9B (fiscal 2024); the current reading is higher than 86% of that period. Haleon PLC Sponsored ADR ranks 2nd of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $2.9B | (0.70%) |
| FY2024 | $2.9B | 17.96% |
| FY2023 | $2.5B | 14.14% |
| FY2022 | $2.2B | 19.46% |
| FY2021 | $1.8B | (4.86%) |
| FY2020 | $1.9B | 87.56% |
| FY2019 | $1.0B | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $1.2B | 3.51% |
| Jun 2025 | $1.2B | (10.43%) |
| Jun 2024 | $1.3B | 73.62% |
| Jun 2023 | $771.3M | (64.55%) |
| 2 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.0B |
| HLN Haleon PLC Sponsored ADR | $4.6B |
| VTRS Viatris Inc. compare | $2.4B |
| ZTS Zoetis Inc. compare | $2.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.3B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.0B |
| UTHR United Therapeutics Corporation compare | $867.2M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement